pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$JAZZJazz Pharmaceuticals plc

$JAZZ216.26+0.13%
Dublin, IEupdated 18d ago

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 4
  • tagOncology2 co-mentions · 1 sources
  • tagPulmonology1 co-mentions · 1 sources
  • tagNSCLC1 co-mentions · 1 sources
  • drugdurvalumab1 co-mentions · 1 sources
pipeline
14
marketed
8
phase 3
0
catalysts ytd
5
approvals ytd
1
recalls ytd
0

Pipeline(14)

view full pipeline →
pipeline depth14 products
Phase 1: 3Phase 2: 1Marketed: 8pre_registration: 1Unknown: 1
3Phase 11Phase 28Marketed1pre_registration1Unknown
Marketed
(calcium oxybate + magnesium oxybate + potassium oxybate + sodium oxybate)
Cataplexy
Marketed
(cytarabine hydrochloride + daunorubicin hydrochloride)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Marketed
Rylaze
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leuk…
Marketed
SODIUM OXYBATE
Cataplexy
Marketed
cannabidiol
Infantile Spasm (West Syndrome)
Cannabinoid receptor 1
Marketed
defibrotide sodium
Hepatic Veno-Occlusive Disease
Marketed
dordaviprone hydrochloride
Glioma
Marketed
lurbinectedin
Ewing Sarcoma
Phase 2
cannabidivarin
Autism Spectrum Disorder (ASD)
Phase 1
JZP-3507
Ependymoma
Phase 1
JZP-898
Gastroesophageal (GE) Junction Carcinomas
Phase 1
flezurafenib
Hematological Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase4A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsycompletedn=155
  • phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participantsrecruitingn=86
  • phase3ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)recruitingn=510
  • phase2A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningiomanot yet recruitingn=30
  • phase1A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1terminatedn=6
  • phase4A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complexactive not recruitingn=79
  • phase2A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCnot yet recruitingn=50
  • —To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)completedn=272
🐶 Hiring Signal
No open roles indexed yet — view Jazz Pharmaceuticals plc jobs →

News

  • 8 companies hiring in North Carolina now
    Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.
    biospace · 2d ago
  • BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
    BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…
    fiercebiotech · 9d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 10d ago
  • 6 potential blockbusters that could pave China’s path to 2030 ambitions
    In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…
    biospace · 16d ago
  • New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
    Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.
    biospace · 21d ago
  • Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal
    After shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara…
    endpoints · 21d ago
  • With Setara, the team behind Actio opens its second act
    The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy prog…
    biopharma_dive · 21d ago
  • Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series A
    Setara Biosciences, a privately held spinout formed following Jazz Pharmaceuticals' acquisition of Actio Biosciences in September, has raised $90 million in series A financing to advance its clinic…
    fiercebiotech · 22d ago
  • Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs
    Plus news about Hutchmed, Johnson & Johnson, Jazz Pharmaceuticals, Novartis, Roche and Oruka Therapeutics. Aspen, Bambusa both eye $135M IPOs: Aspen Neuroscience plans to sell 9.38 million shares {…
    endpoints · 25d ago
  • Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
    Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
    biospace · 28d ago
view all news mentions →
identifiers
ticker
$JAZZ
SEC CIK
0001232524
country
IE
source
sec_tickers
top tags
Oncology8Cardiology2NSCLC2Colorectal Cancer1Dermatology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 5m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?